In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
4th October 2024 Uncategorised 0 In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi’s CAD drug Enjaymo
fkansteiner
Fri, 10/04/2024 – 09:38
More: In sustained rare disease push, Recordati lays out 5M upfront to acquire Sanofi's CAD drug Enjaymo
Source: fierce